Alpha Tau Medical (DRTS) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Technology and clinical innovation

• Developed a unique local alpha particle radiotherapy for solid tumors, overcoming previous limitations of alpha particles' short range by controlled release of radioisotopes within tumors.

• Demonstrated efficacy across over 20 tumor types preclinically, with no observed non-responders, and strong safety profile in hundreds of treated tumors.

• Achieved regulatory approval in Israel for skin and oral cavity squamous cell carcinoma; submitted for approval in Japan and conducting pivotal U.S. study for recurrent cutaneous SCC.

• Innovative delivery devices allow minimally invasive, precise placement of alpha emitters in internal organs like pancreas and brain, integrating with existing clinical workflows.

• Early clinical data show high response rates, including 100% complete response in some studies, and minimal adverse events.

Strategic focus and pipeline

• Strategy targets three pillars: localized unresectable tumors, high unmet need internal organ cancers, and metastatic disease.

• Expanding indications to pancreas, liver, lung, prostate, and brain, with ongoing trials in Canada, Israel, and Jerusalem.

• Pivotal U.S. study in skin SCC expected to complete recruitment mid-year, with marketing submission targeted for early 2026.

• Upcoming R&D update to present interim data from pancreatic and combination immunotherapy studies, with 35-40 patient data sets.

• Exploring combination with immunotherapies (e.g., pembrolizumab) to trigger systemic anti-tumor responses, with ongoing studies benchmarking against KEYNOTE-048 results.

Financial and operational highlights

• Raised $104 million since going public in March 2022; $68 million cash as of Q3, supporting operations for several years.

• Maintains a lean structure with 130-135 employees and ~$5 million quarterly cash burn, supporting 15+ clinical programs.

• Accelerating development plans contingent on positive upcoming data, with confidence in current financial position.